Die Bedeutung des glutamatergen Systems für Pathophysiologie und Pharmakotherapie der Depression: präklinische und klinische Daten

G. Paslakis; P. Gass; M. Deuschle

doi:10.1055/s-0029-1245770

Fortschritte der Neurologie · Psychiatrie, Inhaltsverzeichnis

Fortschr Neurol Psychiatr 2011; 79(4): 204-212
DOI: 10.1055/s-0029-1245770

Übersicht

Die Bedeutung des glutamatergen Systems für Pathophysiologie und Pharmakotherapie der Depression: präklinische und klinische Daten

The Role of the Glutamatergic System in Pathophysiology and Pharmacotherapy for Depression: Preclinical and Clinical DataG. Paslakis¹ , P. Gass¹ , M. Deuschle¹

¹Klinik für Psychiatrie und Psychotherapie, Zentralinstitut für Seelische Gesundheit, Mannheim

Abstract

Zusammenfassung

Dem glutamatergen System wird eine zunehmende Rolle in der Pathophysiologie affektiver Störungen zugeschrieben. Der Neurotransmitter Glutamat ist der wichtigste exzitatorische Transmitter im zentralen Nervensystem. An der Regulation des glutamatergen Systems sind Gliazellen maßgeblich beteiligt. In verschiedenen Untersuchungen wurde eine Dysfunktion bzw. reduzierte Anzahl von Gliazellen bei Patienten mit depressiver Störung beschrieben. Daraus könnte sich bei der Depression eine Überfunktion des glutamatergen Systems mit einer toxisch wirkenden Akkumulation von Glutamat entwickeln. Gängige Antidepressiva greifen in den Glutamat-Metabolismus ein und antiglutamaterge Substanzen (z. B. Riluzol) und NMDA-Rezeptor-Antagonisten (z. B. Ketamin) zeigten antidepressive Wirksamkeit in hauptsächlich präklinischen und einigen klinischen Studien. Weitere Substanzen sind in Prüfung. Diese Übersicht liefert Einblicke über die neuesten Entwicklungen auf diesem Gebiet.

Abstract

An increasing significance has been attributed to the glutamatergic system in the pathophysiology of affective disorders. Glutamate is the most important excitatory neurotransmitter in the central nervous system. Glia cells are crucial regulators of the glutamatergic metabolism. Several studies have reported a dysfunction or reduced number of glia cells in patients suffering from depression. This could result in hyperfunctioning of the glutamatergic system leading to a toxic accumulation of glutamate. Commonly used antidepressants influence the glutamate metabolism and antiglutamatergic substances [e. g., riluzol] and NMDA-receptor antagonists [e. g., ketamine] have shown antidepressant properties in mostly preclinical and some clinical trials. Further substances are currently being investigated. This review provides an insight into the newest developments in this field.

Schlüsselwörter

Glutamat - Depression - NMDA Rezeptor - Ketamin - Gliazelle

Keywords

glutamate - depression - NMDA receptor - ketamine - glia cells

Volltext

Referenzen

Literatur

1 Ustün T B, Ayuso-Mateos J L, Chatterji S et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004; 184 386-392
2 Paykel E S, Brugha T, Fryers T. Size and burden of depressive disorders in Europe. Eur Neuropsychopharmacol. 2005; 15 411-423
3 Kessler R C, Chiu W T, Demler O et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62 617-627
4 Trivedi M H, Rush A J, Wisniewski S R et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D. Implications for clinical practice. Am J Psychiatry. 2006; 163 28-40
5 Thase M E. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr. 2004; 9 808-821
6 DeBattista C. Augmentation and combination strategies for depression. J Psychopharmacol. 2006; 20 11-18
7 Fava M, Rush A J. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom. 2006; 75 139-153
8 Frieling H, Hillemacher T, Demling J H et al. New options in the treatment of depression. Fortschr Neurol Psychiatr. 2007; 75 641-652 Review. German
9 Kugaya A, Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectrom. 2005; 10 808-819
10 Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev. 2009; 61 105-123
11 Pittenger C, Sanacora G, Krystal J H. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets. 2007; 6 101-115
12 Rajkowska G, Miguel-Hidalgo J J. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 2007; 6 219-233
13 Mao L, Tang Q et al. Regulation of MAPK/ERK phosphorylation via ionotropic glutamate receptors in cultured rat striatal neurons. Eur J Neurosci. 2004; 19 1207-1216
14 Mao L, Yang L et al. Role of protein phosphatase 2A in mGluR5-regulated MEK/ERK phosphorylation in neurons. J Biol Chem. 2005; 280 12602-12610
15 Riccio A, Ginty D D. What a privilege to reside at the synapse: NMDA receptor signaling to CREB. Nature Neuroscience. 2002; 5 389-390
16 Chourbaji S, Brandwein C, Gass P. Altering BDNF expression by genetics and/or environment: Impact for emotional and depression-like behaviour in laboratory mice. Neurosci Biobehav Rev. 2010; [Epub ahead of print]
17 Gass P, Hellweg R. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker for affective disorders?. Int J Neuropsychopharmacol. 2010; Epub 2009 Dec 9 13 1-4
18 Hellweg R, Ziegenhorn A, Heuser I et al. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry. 2008; 41 66-71
19 Hardingham G E, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002; 5 405-414
20 Ivanov A, Pellegrino C, Rama S et al. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J Physiol. 2006; 572 789-798
21 Hardingham G E, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002; 5 405-414
22 Kim J S, Schmid-Burgk W, Claus D et al. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr. 1982; 232 299-304
23 Altamura C A, Mauri M C, Ferrara A et al. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry. 1993; 150 1713-1731
24 Mitani H, Shirayama Y, Yamada T et al. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30 1155-1158
25 Levine J, Panchalingam K, Rapoport A et al. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry. 2000; 47 586-593
26 Maes M, Verkerk R, Vandoolaeghe E et al. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand. 1998; 97 302-308
27 Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry. 2007; 62 1310-1316
28 Francis P T, Poynton A, Lowe S L et al. Brain amino acid concentrations and Ca2 + -dependent release in intractable depression assessed antemortem. Brain Res. 1989; 494 315-324
29 Law A J, Deakin J F. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. NeuroReport. 2001; 12 2971-2974
30 Nudmamud-Thanoi S, Reynolds G P. The NR 1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci Lett. 2004; 372 173-177
31 Beneyto M, Kristiansen L V, Oni-Orisan A et al. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology. 2007; 32 1888-1902
32 Feyissa A M, Chandran A, Stockmeier C A et al. Reduced levels of NR 2A and NR 2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33 70-75
33 Karolewicz B, Feyissa A M, Chandran A et al. Glutamate receptors expression in postmortem brain from depressed subjects. Biol Psychiatry. 2009; 65 177
34 Hasler G. Abnormal prefrontal glutamatergic and GABAeric systems in mood and anxiety disorders. Biol Psychiatry. 2009; 65 176-177
35 Karolewicz B, Stockmeier C A, Ordway G A et al. Elevated levels of the NR 2C subunit of the NMDA receptor in the locus coeruleus in depression. Neuropsychopharmacol. 2005; 30 1557-1567
36 Meador-Woodruff J H, Hogg Jr A J, Smith R E. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res Bull. 2001; 55 631-640
37 Choudary P V, Molnar M, Evans S J et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA. 2005; 102 15653-15658
38 Sanacora G, Gueorguieva R, Epperson C N et al. Subtype-specific alterations of -aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004; 61 705-713
39 Auer D P, Putz B, Kraft E et al. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 2000; 47 305-313
40 Ajilore O, Haroon E, Kumaran S et al. Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. Neuropsychopharmacology. 2007; 32 1224-1231
41 Hasler G, Veen J W, Tumonis van der T et al. Reduced prefrontal glutamate/glutamine and -aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007; 64 193-200
42 Block W, Träber F, Widdern von O et al. Proton MR spectroscopy of the hippocampus at 3T in patients with unipolar major depressive disorder: correlates and predictors of treatment responses. Int J Neuropsychopharmacol. 2009; 12 415-422
43 Kendler K S, Kuhn J, Prescott C A. The interrelationship of neuroticism, sex, and stressful life events in the prediction of episodes of major depression. Am J Psychiatry. 2004; 161 631-636
44 Sapolsky R M. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry. 2000; 48 755-765
45 Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry. 2002; 51 775-787
46 Bagley J, Moghaddam B. Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam. Neuroscience. 1997; 77 65-73
47 Banasr M, Valentine G W, Li X Y et al. Chronic unpredictable stress decreases cell proliferation in the cerebral cortex of the adult rat. Biol Psychiatry. 2007; 62 496-504
48 Czeh B, Lucassen P J. What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated?. Eur Arch Psychiatry Clin Neurosci. 2007; 257 250-60
49 Czeh B, Muller-Keuker J I, Rygula R et al. Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology. 2007; 32 1490-1503
50 Nowak G, Trullas R, Layer R T et al. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther. 1993; 265 1380-1386
51 Nowak G, Li Y, Paul I A. Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment. Eur J Pharmacol. 1996; 295 75-85
52 Nowak G, Legutko B, Skolnick P et al. Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. Eur J Pharmacol. 1998; 342 367-370
53 Paul I A, Nowak G, Layer R T et al. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther. 1994; 269 95-102
54 Skolnick P, Layer R T, Popik P et al. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry. 1996; 29 23-26
55 Boyer P A, Skolnick P, Fossom L H. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. J Mol Neurosci. 1998; 10 219-233
56 Michael-Titus A T, Bains S, Jeetle J et al. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex – a possible mechanism of neuroprotection in major depression?. Neuroscience. 2000; 100 681-684
57 Tokarski K, Bobula B, Wabno J et al. Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex. Neuroscience. 2008; 153 789-795
58 Golembiowska K, Dziubina A. Effect of acute and chronic administration of citalopram on glutamate and aspartate release in the rat prefrontal cortex. Pol J Pharmacol. 2000; 52 441-448
59 Sernagor E, Kuhn D, Vyklicky Jr L et al. Open channel block of NMDA receptor responses evoked by tricyclic antidepressants. Neuron. 1989; 2 1221-1227
60 Cai Z, McCaslin P P. Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate- and Nmethyl- D-aspartate-induced intracellular Ca2 + levels in neuronal culture. Eur J Pharmacol. 1992; 219 53-57
61 Watanabe Y, Saito H, Abe K. Tricyclic antidepressants block NMDA receptor-mediated synaptic responses and induction of long-term potentiation in rat hippocampal slices. Neuropharmacology. 1993; 32 479-486
62 Takebayashi M, Kagaya A, Inagaki M et al. Effects of antidepressants on gamma-aminobutyric acid- and N-methyl-D-aspartate-induced intracellular Ca(2 + ) concentration increases in primary cultured rat cortical neurons. Neuropsychobiology. 2000; 42 120-126
63 Bonanno G, Giambelli R, Raiteri L et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci. 2005; 25 3270-3279
64 Szasz B K, Mike A, Karoly R et al. Direct inhibitory effect of fluoxetine on N-methyl-D-aspartate receptors in the central nervous system. Biol Psychiatry. 2007; 62 1303-1309
65 Mayer A, Szasz B K, Kiss J P. Inhibitory effect of antidepressants on the NMDA-evoked ([3] H)noradrenaline release from rat hippocampal slices. Neurochem Int. 2009; 55 383-388
66 Svenningsson P, Tzavara E T, Witkin J M et al. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci USA. 2002; 99 3182-3187
67 Svenningsson P, Bateup H, Qi H et al. Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. Eur J Neurosci. 2007; 26 3509-3517
68 Du J, Suzuki K, Wei Y et al. The Anticonvulsants lamotrigine, riluzole and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology. 2007; 32 793-802
69 Martinez-Turrillas R, Frechilla D, De lRio J. Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology. 2002; 43 1230-1237
70 Barbon A, Popoli M, La V ia L et al. Regulation of editing and expression of glutamate alpha-amino-propionic-acid [AMPA]/kainate receptors by antidepressant drugs. Biol Psychiatry. 2006; 59 713-720
71 Bobula B, Tokarski K, Hess G. Repeated administration of antidepressants decreases field potenzials in rat frontal cortex. Neuroscience. 2003; 120 765-769
72 Bobula B, Hess G. Antidepressant treatments-induced modifications of glutamatergic transmission in rat frontal cortex. Pharmacol Rep. 2008; 60 865-871
73 Dixon J F, Hokin L E. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci USA. 1998; 95 8363-8368
74 Greenhill S D, Jones R S. Diverse antiepileptic drugs increase the ratio of background synaptic inhibition to excitation and decrease neuronal excitability in neurones of the rat entorhinal cortex in vitro. Neuroscience. 2010; 167 456-474
75 Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990; 185 1-10
76 Kos T, Legutko B, Danysz W et al. Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice. J Pharmacol Exp Ther. 2006; 318 1128-1136
77 Chaturvedi H K, Bapna J S, Chandra D. Effect of fluvoxamine and N-methyl-Daspartate receptor antagonists on shock-induced depression in mice. Indian J Physiol Pharmacol. 2001; 45 199-207
78 Yilmaz A, Schulz D, Aksoy A et al. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav. 2002; 71 341-344
79 Maeng S, Zarate Jr C A, Du J et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of &alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008; 63 349-352
80 Garcia L S, Comim C M, Valvassori S S et al. Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels. Basic Clin Pharmacol Toxicol. 2008; 103 502-506
81 Garcia L S, Comim C M, Valvassori S S et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32 140-144
82 Engin E, Treit D, Dickson C T. Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience. 2009; 161 359-369 Erratum in: Neuroscience 2009; 162: 1438 – 1439
83 Kos T, Popik P, Pietraszek M et al. Effect of 5-HT3 receptor antagonist MDL 72 222 on behaviors induced by ketamine in rats and mice. Eur Neuropsychopharmacol. 2006; 16 297-310
84 Maj J, Rogóz Z. Synergistic effect of amantadine and imipramine in the forced swimming test. Pol J Pharmacol. 2000; 52 111-114
85 Almeida R C, Souza D G, Soletti R C et al. Involvement of PKA, MAPK/ERK and CaMKII, but not PKC in the acute antidepressant-like effect of memantine in mice. Neurosci Lett. 2006; 395 93-97
86 Rogoz Z, Skuza G, Maj J et al. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology. 2002; 42 1024-1030
87 Banasr M, Chowdhury G M, Terwilliger R et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioural deficits by the glutamate-modulating drug riluzole. Mol Psychiatry. 2008; [Epub ahead of print]
88 Alt A, Witkin J M, Bleakman D. A role for AMPA receptors in mood disorders. Curr Pharm Des. 2005; 11 1511-1527
89 Bleakman D, Alt A, Witkin J M. AMPA receptors in the therapeutic management of depression. CNS Neurol Disord Drug Targets. 2007; 6 117-126
90 O’Neill M J, Witkin J M. AMPA receptor potentiators: application for depression and Parkinson’s disease. Curr Drug Targets. 2007; 8 603-620
91 Chourbaji S, Vogt M A, Fumagalli F et al. AMPA receptor subunit 1 [GluR-A] knockout mice model the glutamate hypothesis of depression. FASEB J. 2008; 22 3129-3134
92 Belozertseva V, Kos T, Popik P et al. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol. 2007; 17 172-179
93 Li X, Need A B, Baez M et al. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther. 2006; 319 254-259
94 Chaki S, Yoshikawa R, Hirota S et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology. 2004; 46 457-467
95 Bespalov A Y, Gaalen M M, Sukhotina I A et al. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341 495, in animal models of anxiety and depression. Eur J Pharmacol. 2008; 592 96-102
96 Pałucha van A, Tatarczyńska E, Brański P et al. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology. 2004; 46 151-159
97 Palucha A, Klak K, Branski P et al. Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology. 2007; 194 555-562
98 Cryan J F, Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov. 2005; 4 775-790
99 Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflugers Arch. 1991; 419 603-609
100 Zarate Jr C A, Payne J L, Quiroz J et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004; 161 171-174
101 Sanacora G, Kendell S F, Fenton L et al. Riluzole augmentation for treatment-resistant depression. Am J Psychiatry. 2004; 161 2132
102 Zarate Jr C A, Quiroz J A, Singh J B et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005; 57 430-432
103 Mathew S J, Amiel J M, Coplan J D et al. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry. 2005; 162 2379-2381
104 Mathew S J, Murrough J W, aan het Rot M et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010; 13 71-82
105 Ferguson J M, Shingleton R N. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol. 2007; 30 136-144
106 Zarate Jr C A, Singh J B, Quiroz J A et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006; 163 153-155
107 Muhonen L H, Lönnqvist J, Juva K et al. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry. 2008; 69 392-399
108 Berman R M, Cappiello A, Anand A et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000; 47 351-354
109 Zarate Jr C A, Singh J B, Carlson P J et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63 856-864
110 Paslakis G, Gilles M, Meyer-Lindenberg A et al. Oral Administration of the NMDA Receptor Antagonist S-Ketamine as Add-On Therapy of Depression: A Case Series. Pharmacopsychiatry. 2010; 43 33-35
111 Salvadore G, Cornwell B R, Colon-Rosario V et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry. 2009; 65 289-295
112 Kinsler R, Duman R S. Acute ketamine administration increases VEGF expression in the hippocampus: potenzial role in the rapid antidepressant effects of ketamine. Abstract of Society for Neuroscience Meeting at Washington DC 2008 ; #56.14
113 Warner-Schmidt J L, Duman R S. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA. 2007; 104 4647-4652
114 Machado-Vieira R, Yuan P, Brutsche N et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry. 2009; ; [Epub ahead of print]
115 Stahl S M. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition?. J Clin Psychiatry. 2008; 69 1673-1674
116 Borza I, Domány G. NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore. Curr Top Med Chem. 2006; 6 687-695
117 Inta D, Trusel M, Riva M A et al. Differential c-Fos induction by different NMDA receptor antagonists with antidepressant efficacy: potenzial clinical implications. Int J Neuropsychopharmacol. 2009; 12 1133-1136
118 Preskorn S H, Baker B, Kolluri S et al. An innovative design to establish proof of concept of the antidepressant effects of the NR 2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008; 28 631-637
119 Mineur Y S, Picciotto M R, Sanacora G. Antidepressant-like effects of ceftriaxone in male C 57BL/ 6J mice. Biol Psychiatry. 2007; 61 250-252
120 Rothstein J D, Patel S, Regan M R et al. β-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005; 433 73-77
121 Berk M, Copolov D L, Dean O et al. N-acetyl cysteine for depressive symptoms in bipolar disorder – a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008; 64 468-475

Dr. Georgios Paslakis

Klinik für Psychiatrie und Psychotherapie

Zentralinstitut für Seelische Gesundheit

J5

68159 Mannheim

eMail: Georgios.Paslakis@zi-mannheim.de